Mirae Asset Global Etfs Holdings Ltd. Arcutis Biotherapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 66,236 shares of ARQT stock, worth $1.32 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66,236
Previous 71,417
7.25%
Holding current value
$1.32 Million
Previous $1.12 Million
16.85%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ARQT
# of Institutions
240Shares Held
129MCall Options Held
407KPut Options Held
216K-
Suvretta Capital Management, LLC New York, NY11.5MShares$230 Million5.56% of portfolio
-
Jennison Associates LLC11.1MShares$221 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$214 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$197 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$172 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.2B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...